Globenewswire
Search documents
HPQ Silicon Announces Non-Brokered Private Placement Offering of up to $3M
Globenewswire· 2026-02-23 21:12
MONTREAL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. (“HPQ” or the “Company”) (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), an advanced materials technology company developing innovative, low-emission processes for the production of high-purity silicon and silica used in energy storage, electronics, and industrial applications, is pleased to announce a non-brokered private placement (the “Offering”) of up to 18,181,819 units (each, a “Unit”) at a price of $0.165 CAD per Unit for agg ...
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages PennyMac Financial Services, Inc. Investors to Inquire About Securities Class Action Investigation – PFSI
Globenewswire· 2026-02-23 21:12
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. (NYSE: PFSI) resulting from allegations that PennyMac may have issued materially misleading business information to the investing public. SO WHAT: If you purchased PennyMac securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fe ...
BlackRock TCP Capital Corp. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 6, 2026 to Discuss Your Rights – TCPC
Globenewswire· 2026-02-23 21:11
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BlackRock TCP Capital Corp. ("BlackRock TCP" or the "Company") (NASDAQ: TCPC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BlackRock TCP investors who were adversely affected by alleged securities fraud between November 6, 2024 and January 23, 2026. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/bl ...
ROSEN, A RANKED AND LEADING FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE
Globenewswire· 2026-02-23 21:11
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...
Shareholder of Empery Digital Inc. Calls for Immediate Resignation of CEO and Entire Board of Directors
Globenewswire· 2026-02-23 21:10
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tice P. Brown, a 9% stockholder of Empery Digital Inc. (NASDAQ:EMPD) sent the following letter to the Board of Directors of Empery Digital Inc. February 23, 2026 To the Board of Directors of Empery Digital Inc. I currently beneficially own 9.8% of Empery Digital Inc. This week the Management of Empery Digital Inc. made a private and unsolicited bid to me to repurchase 100% of my stock for a purchase price equal to 100% of mNAV, a large premium to prevailing market ...
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance
Globenewswire· 2026-02-23 21:09
Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (all comparisons are to the prior ...
Lost Money on CoreWeave, Inc.(CRWV)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
Globenewswire· 2026-02-23 21:09
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in CoreWeave, Inc. ("CoreWeave, Inc." or the "Company") (NASDAQ: CRWV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of CoreWeave, Inc. investors who were adversely affected by alleged securities fraud between March 28, 2025 and December 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/coreweave-i ...
Levi & Korsinsky, LLP: High-Risk Merchant Concentration Practices at Center of Paysafe Securities Litigation
Globenewswire· 2026-02-23 21:08
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Paysafe Limited (NYSE: PSFE) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between March 4, 2025 and November 12, 2025. Click here to learn more about this case. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. The global digital payments industry processes trillions of dollars annually, requiring careful risk segmentation by merchant ...
Contact Levi & Korsinsky by April 14, 2026 Deadline to Join Class Action Against REGENXBIO Inc. (RGNX)
Globenewswire· 2026-02-23 21:07
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of REGENXBIO investors who were adversely affected by alleged securities fraud between February 9, 2022 and January 27, 2026. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/regenxbio-inc-lawsuit-s ...
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
Globenewswire· 2026-02-23 21:05
Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9%. Fourth qu ...